Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The response’s safety-warning claims (serious infections, increased mortality, malignancy, MACE, and thrombosis) are fully supported by the provided FDA label excerpts (Sections 5.1–5.5 and Section 6), with no stated contradictions and no unsupported assertions detected.
Category Scores
Accurate Statements
Serious and sometimes fatal infections may occur; serious infections include bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens, including TB and other mycobacterial infections.
Supported by Label Section 5.1 (Serious Infections).
Increased risk of mortality may occur, including sudden cardiovascular death in a specified RA Safety Study 1 population.
Supported by Label Section 5.2 (Increased Risk of Mortality).
Malignancies and lymphoproliferative disorders may occur, including lymphomas and solid cancers; malignancy and lung cancer/lymphoma rates were higher in RA Safety Study 1 and additional increased risk for current/past smokers.
Supported by Label Section 5.3 (Malignancy and Lymphoproliferative Disorders).
Major adverse cardiovascular events may occur; MACE is defined as cardiovascular death, non-fatal MI, and non-fatal stroke, and the label advises considering benefits/risks and discontinuing after MI or stroke.
Supported by Label Section 5.4 (Major Adverse Cardiovascular Events).
Thrombosis may occur, including pulmonary embolism (PE), deep venous thrombosis (DVT), and arterial thrombosis; many events were serious and some resulted in death; patients should be promptly evaluated for symptoms and tofacitinib discontinued in symptomatic patients; avoid use in patients at increased risk.
Supported by Label Section 5.5 (Thrombosis).
Section 6 lists these clinically significant adverse reactions as described elsewhere in labeling (mapping to Sections 5.1–5.5).
Supported by Label Section 6 (Adverse Reactions list).
Unsupported Statements
Contradictions
Important Omissions
No evaluation of boxed warning content or any dosing/administration, contraindications, monitoring specifics, or drug interaction statements was performed (content not provided in the response and not addressed in the provided label excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims align with the provided label excerpts for serious infections, mortality, malignancy, MACE, and thrombosis; no incorrect or contradictory safety statements were made within the scope of the provided content.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Safety alignment is strong, but the response does not evaluate other label safety elements beyond the warnings discussed (e.g., contraindications, dosing, monitoring, administration instructions, storage/handling, drug interactions).
Suggested Improvement
If auditing broader label adherence, include evaluation coverage for additional sections relevant to safe use (contraindications, dosing/administration, monitoring, drug interactions, and complete boxed warning context), using the corresponding label excerpts.